The University of Oxford’s ChAdOx1 nCoV-19 vaccine induces a strong immune response with no serious adverse reactions, preliminary findings of a phase I/II trial published in The Lancet have suggested.
Clarithromycin linked to increased haemorrhage risk in patients treated with direct oral anticoagulantsSubscription
Older adults taking direct oral anticoagulants are more likely to be admitted to hospital for haemorrhage after receiving clarithromycin compared with azithromycin, a study published in JAMA Internal Medicine has suggested.
Vitamin D may protect against colitis adverse events in patients taking immune checkpoint inhibitorsSubscription
People with melanoma who take immune checkpoint inhibitors are less likely to develop colitis if they are taking vitamin D supplements at treatment initiation, a study published in the journal Cancer has suggested
The COVID-19 pandemic has led to innovation in anticipatory prescribing practices within community palliative care, the results of a survey in BMJ Supportive & Palliative Care have shown.
Patients hospitalised with COVID-19 who take statins are less likely to die than those who do not, a retrospective study published in Cell Metabolism suggests.
Disproportionate impact of COVID-19 on BAME populations not explained by cardiometabolic factors, vitamin D or deprivation, researchers findSubscription
Variations in cardiometabolic factors, vitamin D levels and socioeconomic or behavioural factors do not adequately explain why COVID-19 disproportionately affects black, Asian and minority ethnic populations.
People with inflammatory bowel disease have a significantly higher risk of developing dementia later in life, a study in Gut has suggested.
Biological therapies secukinumab and adalimumab are similarly effective at improving the musculoskeletal symptoms of psoriatic arthritis, a head-to-head trial suggests.
Medication overuse headache is best treated with a combination of analgesic withdrawal and pharmaceutical prophylaxis, the authors of a study in JAMA Neurology have said.
Sodium-glucose co-transporter 2 inhibitors are associated with a lower incidence of serious renal events in people with diabetes, a study in the BMJ has suggested.